Skip to main content
Erschienen in: Medical Oncology 4/2011

01.12.2011 | Original Paper

Metastatic factors for Krukenberg tumor: a clinical study on 102 cases

verfasst von: Li Qiu, Ting Yang, Xue-Hua Shan, Ming-Bai Hu, Yan Li

Erschienen in: Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

To investigate factors associated with gastrointestinal (GI) carcinomas metastasizing to ovaries to form Krukenberg tumor. Among the 102 cases of Krukenberg tumor due to GI cancers, there were 41 cases synchronously diagnosed, 43 cases with primary tumor identified first and 18 cases with ovarian tumor identified first. Metastatic factors of 43 cases of metachronous Krukenberg tumor were analyzed with univariate and multivariate methods. Of the 43 patients, the median age at diagnosis of Krukenberg tumor was 42 years (range, 21–72). Stomach is the most common primary site (58.1%), followed by colon (25.6%) and rectum (16.3%). Most of the patient was in premenopausal state (81.4%) and had bilateral ovaries involved (67.4%). The overall median metastasis-free time in T3 group (17.0 months) was significantly longer than that in T4 group (10.0 months) (P = 0.003). Univariate analysis identified tumor invasion depth and ascites as significant factors for metastasis. Multivariate analysis confirmed that invasion depth was the only significant metastatic factor (Relative Risk: 3.2, P = 0.004). Primary carcinomas T stage is the most important predictor of Krukenberg tumor from GI cancer.
Literatur
1.
Zurück zum Zitat Kim HK, Heo DS, Bang YJ, Kim NK. Prognostic factors of Krukenberg’s tumor[J]. Gynecol Oncol. 2001;82(1):105–9.PubMedCrossRef Kim HK, Heo DS, Bang YJ, Kim NK. Prognostic factors of Krukenberg’s tumor[J]. Gynecol Oncol. 2001;82(1):105–9.PubMedCrossRef
2.
Zurück zum Zitat Mateş IN, Iosif C, Bănceanu G, et al. Features of Krukenberg-type tumors—clinical study and review. Chirurgia (Bucur). 2008;103(1):23–38. Mateş IN, Iosif C, Bănceanu G, et al. Features of Krukenberg-type tumors—clinical study and review. Chirurgia (Bucur). 2008;103(1):23–38.
3.
Zurück zum Zitat Yook JH, Oh ST, Kim BS. Clinical prognostic factors for ovarian metastasis in women with gastric cancer. Hepatogastroenterology. 2007;54(75):955–9.PubMed Yook JH, Oh ST, Kim BS. Clinical prognostic factors for ovarian metastasis in women with gastric cancer. Hepatogastroenterology. 2007;54(75):955–9.PubMed
4.
Zurück zum Zitat Serov SF, Scully RE. Histologic typing of ovarian tumors, vol. 9. Geneva: World Health Organization; 1973. p. 17–8. Serov SF, Scully RE. Histologic typing of ovarian tumors, vol. 9. Geneva: World Health Organization; 1973. p. 17–8.
5.
Zurück zum Zitat Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med. 2006;130(11):1725–30.PubMed Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med. 2006;130(11):1725–30.PubMed
6.
Zurück zum Zitat Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol. 2006;30(3):277–99.PubMed Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol. 2006;30(3):277–99.PubMed
7.
Zurück zum Zitat Khunamornpong S, Lerwill MF, Siriaunkgul S, et al. Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol. 2008;27(3):366–79.PubMedCrossRef Khunamornpong S, Lerwill MF, Siriaunkgul S, et al. Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol. 2008;27(3):366–79.PubMedCrossRef
8.
Zurück zum Zitat Kim WY, Kim TJ, Kim SE, et al. The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):97–101.PubMedCrossRef Kim WY, Kim TJ, Kim SE, et al. The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):97–101.PubMedCrossRef
9.
Zurück zum Zitat Tan KL, Tan WS, Lim JF, et al. Krukenberg tumors of colorectal origin: a dismal outcome—experience of a tertiary center. Int J Colorectal Dis. 2010;25(2):233–8.PubMedCrossRef Tan KL, Tan WS, Lim JF, et al. Krukenberg tumors of colorectal origin: a dismal outcome—experience of a tertiary center. Int J Colorectal Dis. 2010;25(2):233–8.PubMedCrossRef
10.
Zurück zum Zitat Kim KH, Kim CD, Lee HS, Hyun JH, Kim YS, Kim IS. Bilateral ovarian carcinoma metastatic from the ampulla of vater: a rare Krukenberg tumor. J Korean Med Sci. 1999;14(2):220–2.PubMed Kim KH, Kim CD, Lee HS, Hyun JH, Kim YS, Kim IS. Bilateral ovarian carcinoma metastatic from the ampulla of vater: a rare Krukenberg tumor. J Korean Med Sci. 1999;14(2):220–2.PubMed
11.
Zurück zum Zitat Mandai M, Konishi I, Tsuruta Y, et al. Krukenberg tumor from an occult appendiceal adenocarcinoid: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2001;97(1):90–5.PubMedCrossRef Mandai M, Konishi I, Tsuruta Y, et al. Krukenberg tumor from an occult appendiceal adenocarcinoid: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2001;97(1):90–5.PubMedCrossRef
12.
Zurück zum Zitat Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol. 2004;93(1):87–91.PubMedCrossRef Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol. 2004;93(1):87–91.PubMedCrossRef
13.
Zurück zum Zitat Irving JA, Vasques DR, McGuinness TB, Young RH. Krukenberg tumor of renal pelvic origin: report of a case with selected comments on ovarian tumors metastatic from the urinary tract. Int J Gynecol Pathol. 2006;25(2):147–50.PubMedCrossRef Irving JA, Vasques DR, McGuinness TB, Young RH. Krukenberg tumor of renal pelvic origin: report of a case with selected comments on ovarian tumors metastatic from the urinary tract. Int J Gynecol Pathol. 2006;25(2):147–50.PubMedCrossRef
14.
Zurück zum Zitat Krichen Makni S, Abbes K, Khanfir A, Frikha M, Sellami Boudawara T. Metastatic signet ring cell carcinoma to the breast from stomach. Cancer Radiother. 2007;11(5):276–9.PubMedCrossRef Krichen Makni S, Abbes K, Khanfir A, Frikha M, Sellami Boudawara T. Metastatic signet ring cell carcinoma to the breast from stomach. Cancer Radiother. 2007;11(5):276–9.PubMedCrossRef
15.
Zurück zum Zitat Christopoulos C, Skopeliti M, Rotas E, et al. Non-Hodgkin lymphoma involving stomach and ovary: extending the Krukenberg tumor concept. Ann Hematol. 2009;89(1):101–2.CrossRef Christopoulos C, Skopeliti M, Rotas E, et al. Non-Hodgkin lymphoma involving stomach and ovary: extending the Krukenberg tumor concept. Ann Hematol. 2009;89(1):101–2.CrossRef
16.
Zurück zum Zitat Kakushima N, Kamoshida T, Hirai S, et al. Early gastric cancer with Krukenberg tumor and review of cases of intramucosal gastric cancers with Krukenberg tumor. J Gastroenterol. 2003;38(12):1176–80.PubMedCrossRef Kakushima N, Kamoshida T, Hirai S, et al. Early gastric cancer with Krukenberg tumor and review of cases of intramucosal gastric cancers with Krukenberg tumor. J Gastroenterol. 2003;38(12):1176–80.PubMedCrossRef
17.
Zurück zum Zitat McGill FM, Ritter DB, Rickard CS, et al. Krukenberg tumors: can management be improved? Gynecol Obstet Invest. 1999;48(1):61–5.PubMedCrossRef McGill FM, Ritter DB, Rickard CS, et al. Krukenberg tumors: can management be improved? Gynecol Obstet Invest. 1999;48(1):61–5.PubMedCrossRef
18.
Zurück zum Zitat Tazaki T, Nishimura H, Yakushiji M, et al. Histomorphological studies of Krukenberg tumor on early ovarian metastatic lesion. Nippon Sanka Fujinka Gakkai Zasshi. 1990;42(4):353–9.PubMed Tazaki T, Nishimura H, Yakushiji M, et al. Histomorphological studies of Krukenberg tumor on early ovarian metastatic lesion. Nippon Sanka Fujinka Gakkai Zasshi. 1990;42(4):353–9.PubMed
19.
Zurück zum Zitat Asbun HJ, Hughes KS. Management of recurrent and metastatic colorectal carcinoma. Surg Clin North Am. 1993;73(1):145–8.PubMed Asbun HJ, Hughes KS. Management of recurrent and metastatic colorectal carcinoma. Surg Clin North Am. 1993;73(1):145–8.PubMed
20.
Zurück zum Zitat La Fianza A, Alberici E, Pistorio A, Generoso P. Differential diagnosis of Krukenberg tumor using multivariate analysis. Tumori. 2002;88(4):284–7.PubMed La Fianza A, Alberici E, Pistorio A, Generoso P. Differential diagnosis of Krukenberg tumor using multivariate analysis. Tumori. 2002;88(4):284–7.PubMed
Metadaten
Titel
Metastatic factors for Krukenberg tumor: a clinical study on 102 cases
verfasst von
Li Qiu
Ting Yang
Xue-Hua Shan
Ming-Bai Hu
Yan Li
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9610-4

Weitere Artikel der Ausgabe 4/2011

Medical Oncology 4/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.